Q1 2024 Qualitative Update: Performance In Line with Expectations for
Full-Year 2024

waiting on 1901891,news,refinitiv---790ea929-3c21-49b8-8ff9-1aed464daef1
waiting on 1901891,news,acquiremedia---1e491ff3-7da4-4be1-bc7b-b8628d89203e
waiting on 1901891,news,bloomberg5
waiting on 1901891,news,alpha_trading---24efeb43-bac4-4e17-bf16-23d1aa6bb398

   Lonza Group AG / Key word(s): Quarter Results
   Q1 2024 Qualitative Update: Performance In Line with Expectations
   for Full-Year 2024
   14-May-2024 / 07:00 CET/CEST
   Release of an ad hoc announcement pursuant to Art. 53 LR
   The issuer is solely responsible for the content of this
   announcement.
     ____________________________________________________________

   
   Ad hoc announcement pursuant to Art. 53 LR
     * Outlook 2024 remains flat CER sales growth and CORE EBITDA
       margin of high 20s
     * Softer performance in Q1 2024, normalizing across H1 2024
     * Sustained commercial demand in CDMO business with initial
       signs of early-stage recovery
     * Key growth projects due to start in 2024 progressing in line
       with plan
     * Revised definition of three Alternative Performance Measures
       from H1 2024

   Basel, Switzerland, 14 May 2024 - In its quarterly qualitative
   update, Lonza reported a softer Q1, with performance across H1
   expected to align with the Full-Year 2024 trajectory.

   Lonza confirms its Outlook 2024 at flat sales growth in CER and
   Core EBITDA margin of high 20s. H2 2024 sales are expected to be
   solid, reflecting the timing of batch releases.

   In Biologics, there was good momentum across the division with
   sustained commercial demand, while clinical demand remained
   softer, despite early signs of biotech funding recovery. The
   Small Molecules division also saw strong commercial demand, and
   made continued progress on strategic investments. Cell & Gene
   delivered improved commercial and operational performance in Cell
   & Gene Technology, while market headwinds impacted Bioscience
   primarily in its media business. Finally, the performance of the
   Capsules & Health Ingredients division was softer than expected
   due to a combination of weaker demand for pharma hard capsules in
   western markets, and lower margins in its nutraceutical business
   despite improved demand.

   Lonza's key growth projects are progressing in line with plan.
   Operations are expected to commence at the large-scale Mammalian
   drug substance and highly potent API facilities in Visp (CH) in
   Q4 2024. Construction is on track at the large-scale commercial
   drug product facility in Stein (CH).

   In Q1 2024, Lonza announced it had signed an agreement to acquire
   the Genentech manufacturing facility in Vacaville (US) from Roche
   for USD 1.2 billion in cash. Lonza plans to invest around CHF 500
   million to upgrade the facility and enhance capabilities at the
   site to accommodate the next generation of mammalian biologics
   therapies. In this context, Mid-Term Guidance 2024 - 2028 sales
   growth range was updated from 11 - 13% CAGR in CER^1 to 12 - 15%.
   All other Mid-Term Guidance metrics are unchanged.

   On 2 April 2024, the Board of Directors was pleased to appoint
   Wolfgang Wienand as the new Chief Executive Officer of Lonza. He
   will join the company during the summer of 2024.

   Albert M. Baehny, CEO ad interim, Lonza, commented: "We made good
   progress in Q1 2024 with the strategic acquisition of the
   large-scale biologics site in Vacaville and the appointment of
   Lonza's new CEO, Wolfgang Wienand. Looking at our industry
   fundamentals, we remain well-positioned to capture value by
   maintaining our focus on growing our commercial offering, while
   managing our costs and maintaining our focus on operational
   excellence."

   Lonza has revised the definition of three Alternative Performance
   Measures including CORE EPS, Free Cash Flow and Divisional CORE
   EBITDA. The new definitions will be reflected in the H1 2024
   reporting process. The changes are designed to enhance
   transparency and efficiency and will not change IFRS reporting.
   Additional information, including Restated Full-Year 2023,
   Half-Year 2023 and Full-Year 2022 results, can be found here.

About Lonza

   Lonza is one of the world's largest healthcare manufacturing
   organizations. Working across five continents, our global
   community of around 18,000 colleagues helps pharmaceutical,
   biotech and nutrition companies to bring their treatments to
   market. United by our vision to bring any therapy to life, we
   support our customers with a combination of technological
   insight, world-class manufacturing, scientific expertise, process
   excellence and innovation. Our work enables our customers to
   develop and commercialize their therapeutic discoveries, allowing
   their patients to benefit from life-saving and life-enhancing
   treatments.

   Our business is structured to meet our customers' complex needs
   across four divisions: Biologics, Small Molecules, Cell & Gene,
   and Capsules & Health Ingredients. Our company generated sales of
   CHF 6.7 billion with a CORE EBITDA of CHF 2.0 billion in
   Full-Year 2023. Find out more at www.lonza.com

   Follow @Lonza on LinkedIn
   Follow @LonzaGroup on X

Lonza Contact Details

   Victoria Morgan
   Head of External Communications
   Lonza Group Ltd
   Tel +41 61 316 2283
   victoria.morgan@lonza.com

   Daniel Buchta
   Head of Investor Relations
   Lonza Group Ltd
   Tel +41 61 316 2985
   daniel.buchta@lonza.com

____________________________________________________________

   End of Inside Information
     ____________________________________________________________

   Language:    English
   Company:     Lonza Group AG
                Münchensteinerstrasse 38
                4052 Basel
                Switzerland
   Phone:       +4161 316 81 11
   Internet:    www.lonza.com
   ISIN:        CH0013841017
   Valor:       1384101
   Listed:      SIX Swiss Exchange
   EQS News ID: 1901891

   End of Announcement EQS News Service
     ____________________________________________________________

1901891 14-May-2024 CET/CEST